Why is Astrazeneca Phar falling/rising?

As of 13-Jun, Astrazeneca Pharma India Ltd's stock price is rising, currently at 10,524.65, reflecting an increase of 346.1 or 3.4%. The stock has recently hit a new 52-week and all-time high of Rs. 10,653.05, outperforming its sector by 3.69%. It has shown a strong performance over the last two days, gaining 5.43%, and has consistently outperformed the benchmark Sensex, with a 1-week return of +7.83% compared to the Sensex's -1.30%. Positive factors contributing to this rise include high management efficiency with a return on equity (ROE) of 19.06%, a low debt-to-equity ratio, and significant growth in net profit of 88.82%. However, there are concerns regarding poor long-term growth potential and falling participation from institutional investors, which may impact future performance.
Broader Market Context: The stock's short-term performance is notably strong, with a 1-week return of +7.83%, contrasting sharply with the Sensex's decline of -1.30%. This indicates that Astrazeneca Pharma is not only performing well in isolation but is also gaining traction against broader market trends. The company's consistent returns over the past three years, including a 65.72% return in the last year, further highlight its resilience and attractiveness to investors, despite some risks associated with valuation and institutional investor participation.